KMT2A and acute lymphoblastic leukemia: High sensitivity of primary B-ALL (non-MLL) samples to BCL-2 inhibition was validated in a separate cohort of adult and pediatric samples treated with ABT-199 or dual BCL-2/BCL-XL inhibitor ABT-263 for 8 hr (Figure S4F).